Peptidream Inc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Peptidream Inc with three other
companies in this sector in Japan:
Japan Tissue Engineering Company Limited
sales of 2.14 billion Japanese Yen [US$19.30 million]
of which 96%
was Regenerative Medicine Products Business),
Trans Genic Inc
(2.30 billion Japanese Yen [US$20.82 million]
of which 50%
was CRO Business), and
Medinet Co., Ltd.
(1.70 billion Japanese Yen [US$15.40 million]
of which 100%
was cell processing).
During the year ended June of 2017, sales at
Peptidream Inc were ¥4.90 billion (US$44.26 million).
increase of 13.1%
versus 2016, when the company's sales were ¥4.33 billion.
This was the fifth consecutive year of sales increases at Peptidream Inc
(and since 2012, sales have increased a total of 1,720%).